OncoTherapy Science, Inc. (FRA:30O)

Market Cap	41.08M +3.1%
Revenue (ttm)	5.51M +99.6%
Net Income	-4.75M
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	3
Open	0.0950
Previous Close	0.1000
Day's Range	0.0950 - 0.0950
52-Week Range	0.0835 - 0.2080
Beta	n/a
RSI	45.38
Earnings Date	Feb 6, 2026

About OncoTherapy Science

OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stag...

• Industry: Commercial Physical and Biological Research
• Founded: 2001
• Employees: 47
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 30O

Financial Performance

In fiscal year 2025, OncoTherapy Science's revenue was 750.00 million, an increase of 22.95% compared to the previous year's 610.00 million. Losses were -815.00 million, -36.72% less than in 2024.

Financial numbers in JPY